<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alfacalcidol (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alfacalcidol (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alfacalcidol (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="16468" href="/d/html/16468.html" rel="external">see "Alfacalcidol (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52871246"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>One Alpha [DSC];</li>
<li>One-Alpha;</li>
<li>SANDOZ Alfacalcidol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F11820954"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Vitamin D Analog</li></ul></div>
<div class="block doa drugH1Div" id="F11821507"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d5dbbc1-7bcb-4c78-a14e-55844fc448e4">Chronic kidney disease-mineral and bone disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease-mineral and bone disorder (hypocalcemia, secondary hyperparathyroidism, or osteodystrophy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Kidney Disease: Improving Global Outcomes (KDIGO) guidelines do not recommend routine use of vitamin D analogs in patients not on dialysis with chronic kidney disease (CKD) stages G3 to G5; it is reasonable to reserve use for patients with CKD stages G4 or G5 and with severe and progressive hyperparathyroidism. Caution is advised to avoid hypercalcemia or elevated phosphate levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30675420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30675420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with moderate to severe chronic kidney disease not yet on dialysis</i>: <b>Note:</b> The magnitude of parathyroid hormone (PTH) response is highly variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22285224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22285224'])">Ref</a></span>). KDIGO guidelines recommend initiating with low doses independent of initial PTH concentration and then titrating based on PTH response while avoiding hypercalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30675420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30675420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 0.25 mcg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); however, lower doses have been reported (eg, 0.25 mcg 3 times <b>weekly</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20090369']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20090369'])">Ref</a></span>); may titrate dose upward in increments of 0.25 mcg/day every 2 months (maximum dose: 1 mcg/day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients on dialysis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initiate carefully; 0.25 mcg once daily is the lowest recommended dose in the manufacturer's labeling and has been reported elsewhere (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18633342','lexi-content-ref-22607568','lexi-content-ref-14671054','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18633342','lexi-content-ref-22607568','lexi-content-ref-14671054','lexi-content-ref-Manu.1'])">Ref</a></span>). If necessary, may titrate dose upward in increments of 0.25 to 0.5 mcg/day every 2 to 4 weeks (maximum dose: 3 mcg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initiate carefully; 0.5 mcg 3 times<b> weekly</b> is the lowest recommended dose in the manufacturer's labeling. If inadequate response, may titrate dose upward in increments of 0.5 to 1 mcg per dialysis (maximum dose: 12 mcg/week).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9a44b31b-f0f8-4953-8a6e-849612e2ae00">Hypoparathyroidism, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoparathyroidism, chronic (off-label use):</b>
<b>Oral:</b> Initial (low end of range): 0.5 mcg/day; may adjust dose carefully in increments of 0.25 to 0.5 mcg/day not more frequently than every 2 to 3 days to achieve desired calcium levels while avoiding hypercalcemia. Usual range: 0.5 to 4 mcg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200','lexi-content-ref-26160136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200','lexi-content-ref-26160136'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients discontinuing recombinant PTH therapy: </i>Significantly increased doses of alfacalcidol and supplemental calcium may be acutely required to prevent severe hypocalcemia, especially if recombinant PTH therapy is discontinued abruptly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25990370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25990370'])">Ref</a></span>); consider using alfacalcidol (and supplemental calcium) at higher doses than the pre-rPTH treatment doses, with careful monitoring of calcium levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26943719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26943719'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990162"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50987498"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dot drugH1Div" id="F11821508"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Predialysis patients: If hypercalcemia develops within the first 2 months of therapy reduce dose to 0.25 mcg every other day; at any other time during therapy,  reduce dose by 50% and discontinue all calcium supplements until serum calcium levels normalize. </p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Dialysis patients: Oral, IV: Discontinue immediately for hypercalcemia; may consider reintroducing therapy at a reduced dose after serum calcium levels normalize. </p></div>
<div class="block adr drugH1Div" id="F11821491"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, decreased libido, hypercholesterolemia, polydipsia, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, constipation, diarrhea, nausea, pancreatitis, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ectopic calcification, nocturia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, drowsiness, fatigue, headache, hyperthermia, metallic taste, psychosis, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia, ostealgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, corneal deposits (calcification), photophobia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, polyuria, renal insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinorrhea</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (Tamiya 2011), hyperphosphatemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hypercalciuria</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis, renal failure syndrome</p></div>
<div class="block coi drugH1Div" id="F11820958"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to 1-α-hydroxyvitamin D<sub>3</sub>, vitamin D or its analogues and derivatives, or any component of the formulation; hypercalcemia; hyperphosphatemia; evidence of vitamin D toxicity</p></div>
<div class="block war drugH1Div" id="F11821489"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of parathyroid hormone (PTH), progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: Monitor calcium levels closely; patients with chronic renal failure are at an increased risk for hypercalcemia. Dose reduction or discontinuation of therapy may be necessary. Withhold calcium supplementation until calcium levels normalize. Discontinue use with hypercalcemia in dialysis patients; may reinstitute therapy at 50% of previous dose 1 week after calcium levels have normalized. Chronic hypercalcemia may result in generalized vascular and soft tissue calcification, exacerbate nephrolithiasis, and has been associated with increased mortality in adults with chronic kidney disease (CKD) (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperphosphatemia: Monitor serum phosphate; in cases of progressively or persistently elevated serum phosphate, the use of phosphate-lowering agents may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular: Avoid prolonged hypercalcemia; may aggravate arteriosclerosis or cardiac valve sclerosis. Use with caution in patients with calcification of pulmonary tissue; may result in cardiac disease. Severe hypercalcemia may increase risk of cardiac arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Granulomatous diseases: Use with caution in patients with granulomatous diseases (eg, sarcoidosis) due to increased sensitivity to vitamin D.</p></div>
<div class="block prod-avail drugH1Div" id="F11820951"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the United States.</p></div>
<div class="block geq drugH1Div" id="F53040755"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block dinfoc drugH1Div" id="F52871247"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">One Alpha: 0.5 mcg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">One-Alpha: 0.25 mcg, 1 mcg [contains sesame oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mcg, 1 mcg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">One-Alpha: 2 mcg/mL (0.5 mL, 1 mL) [contains alcohol, usp, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">One-Alpha: 2 mcg/mL (10 mL) [contains alcohol, usp, methyl hydroxybenzoate]</p></div>
<div class="block adm drugH1Div" id="F11821509"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer oral solution (drops) and capsules with or without food and/or drink. Swallow capsules whole. Do not shake oral solution bottle.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Shake injection solution well (at least 5 seconds) prior to use and administer as bolus IV injection.</p></div>
<div class="block use drugH1Div" id="F11820955"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease-mineral and bone disorder:</b> Management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure</p></div>
<div class="block off-label drugH1Div" id="F52784179"><span class="drugH1">Use: Off-Label: Adult</span><p>Hypoparathyroidism (chronic)</p></div>
<div class="block mst drugH1Div" id="F11820949"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Alfacalcidol may be confused with calcitriol, cholecalciferol, ergocalciferol, paricalcitol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298703"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F11822195"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.  Management: Consider avoiding chronic use of aluminum and aluminum-containing products in patients who are also taking active vitamin D analogs. If coadministered, monitor aluminum status and for signs and symptoms of aluminum-related toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Burosumab: Vitamin D Analogs may enhance the adverse/toxic effect of Burosumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Alfacalcidol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: Alfacalcidol may increase the serum concentration of Magnesium Salts.  Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving alfacalcidol.  If magnesium-containing products must be used with alfacalcidol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the absorption of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.  Management: Consider avoiding chronic use of aluminum and aluminum-containing products, such as sucralfate, in patients who are also taking active vitamin D analogs. If combined, monitor for signs and symptoms of aluminum-related toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F11820956"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F21098355"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Alfacalcidol may be present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F11821516"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary hyperparathyroidism (CKD patients)</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The frequency of serum calcium, phosphate, and parathyroid hormone (PTH) measurements may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for chronic kidney disease-mineral and bone disorder (KDIGO 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>During therapy initiation and dosage adjustments:</b> Frequent monitoring of serum calcium and phosphate levels (eg, at least twice weekly) is recommended (manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>KDIGO guidelines (2017):</b>
<b>Note:</b> During treatment or when biochemical abnormalities are identified more frequent monitoring may be reasonable.</p>
<p style="text-indent:-2em;margin-left:6em;">CKD stage G3a-G3b: Serum calcium and phosphate: Every 6 to 12 months; PTH: Frequency based on baseline level and progression of CKD; alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:6em;">CKD stage G4: Serum calcium and phosphate: Every 3 to 6 months; PTH: Every 6 to 12 months; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH</p>
<p style="text-indent:-2em;margin-left:6em;">CKD stage G5 and G5D: Serum calcium and phosphate: Every 1 to 3 months; PTH: Every 3 to 6 months; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH</p>
<p style="text-indent:-4em;margin-left:6em;">Additionally, during maintenance therapy, periodic 24-hour urinary calcium and phosphate; periodic ophthalmologic exams (manufacturer’s labeling)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoparathyroidism, chronic (off-label use) (Endocrine Society [Brandi 2016]):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Frequency of measurement is dependent upon on how stable a patient is to a given dosage regimen with more frequent measurements (eg, weekly) required initially during dosage titration. Once patient is well controlled, monitoring may be required on a yearly or twice-yearly basis.</p>
<p style="text-indent:-2em;margin-left:6em;">Serum calcium, phosphate, and magnesium; renal function [ie, 24-hour urinary calcium and creatinine, blood urea nitrogen (BUN), measured creatinine clearance or estimated glomerular filtration rate (eGFR)]; renal imaging (every 5 years in asymptomatic patients with a history of renal lithiasis or calcinosis or more frequently as indicated); CNS imaging (basal ganglia and other sites of calcification), ophthalmologic exam, and/or BMD as clinically indicated</p></div>
<div class="block rer drugH1Div" id="F11821515"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Due to the complexity and interdependency of the laboratory parameters used for therapeutic decisions in chronic kidney disease-mineral and bone disorder (CKD-MBD) patients, serial assessments of phosphate, calcium, and parathyroid hormone (PTH) levels should be considered together (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Calcium (total): Adults: Normal range: 8.6 to 10.2 mg/dL (SI: 2.2 to 2.6 mmol/L). Avoid hypercalcemia for chronic kidney disease (CKD) stages G3a-G5D (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Serum phosphate: 3 to 4.5 mg/dL (SI: 1 to 1.5 mmol/L). Lower elevated phosphate levels toward the normal range for CKD stages G3a-G5D (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">PTH:</p>
<p style="text-indent:-2em;margin-left:6em;">CKD stage G3a-G5: Optimal PTH level is unknown; evaluate patients with progressively elevated intact PTH levels or if levels are consistently above the normal range (assay-dependent) (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Dialysis patients: Maintain intact parathyroid hormone (iPTH) within 2 to 9 times the upper limit of normal for the assay used (KDIGO 2017).</p></div>
<div class="block pha drugH1Div" id="F11821701"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Alfacalcidol is rapidly converted to the active metabolite of vitamin D (1,25-dihydroxyvitamin D<sub>3</sub>) in the liver, effectively bypassing renal metabolic conversion; promotes intestinal absorption of calcium and phosphorous, resorption of calcium from the bone, and possibly renal reabsorption of calcium</p></div>
<div class="block phk drugH1Div" id="F11821498"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of effect on intestinal calcium absorption levels: 1,25-(OH)<sub>2</sub> D<sub>3</sub>: 48 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Extensively to vitamin D-binding protein</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to 1,25-(OH)<sub>2</sub> D<sub>3</sub></p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~3 hours in renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak of active vitamin D levels: Oral: 12 hours; IV: 4 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F14190114"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">One alpha | Osteo Alfa</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alfa calcimax | Alpha d3</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol teva | Bondiol | Etalpha</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">One alpha</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">1-alpha leo | Etalpha</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alfad | Sigmacalcidol</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Un alfa</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alfa d | Etalpha</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcido | Alpha d3 | Ao sen | Ao si hui | Bon-one | Etalpha | Fa neng | Gai nuo zhen | Li qing | Lonpryl | Shuang ye hong | Yan di nuo | Yaoyou liqing</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Etalpha</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol cande | Alpha d3</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol 1 a pharma | Alfacalcidol Aristo | Alfacalcidol fairmed healtcare | Alfacalcidol hexal | Alfacalcidol Medice | Alfacalcidol ratiopharm | Alfacalcidol teva | Bondiol | Doss | Einsalpha | Etalpha | One alpha | Onealpha | Tevacidol | Un alfa</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Etalpha</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Etalpha</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3 | Einsalpha | One -alpha</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alfabonid | Alfacareno | Bon one | Bone Care | Calcidol | One alpha | One-alpha | Taminorig</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alfadelta | Etalpha</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol orifarm | Etalpha</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol teva | Un alfa</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alfa d | Alfacalcidol kent | Alpha d | One alpha</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">A-ostin-d3 | Alcidolin | Alestopor | Alpha d3 | Alphabikal | Alphazol | Antebe | Axelanol | Baludol | Biovit | Calcidrops | Calculus | Emarfen | Iasvest | Losefan | Mega-Alpha | One alpha | Ossidrol | Osteovile | V D Bone | Vitocalcit</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alfarol | Alpha d3 | Bon one | One-alpha</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bon one | One alpha</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">One alpha</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alfa-calcirol | Alfabond | Alfacal | Alfacip | Alfarich | Alfaset | Alpha-d3 | Alphadol | Bonydil | Calcit sg | Calfa-d | Gr-alfa | Minroset | One-alpha | Qtr-alfa | Vitalpha | Zaxial</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3 | Dediol | Deril | Diseon | Diserinal | Geniad | Ostidil-d3 | Sefal</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">One alpha | Osteo Alfa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alcadol | Alfacalcidol amel | Alfagard | Alfarol | Alfasuly | Alsiodol | Alsiodol amel | Alsiodol choseido | Alsiodol daiko | Alsiodol kayaku | Alsiodol merck hoei | Alsiodol ohta | Alsiodol taiyo | Alsiodol tatumi | Alsiodol teiyaku | Antul | Arowthol merck hoei | Arowtohl | Arowtohl kaken | Asravtal | Calcitamin | Calcitamin hexal | Calcitamin takata | Calfalead taiyo | Calfalead towa | Calfina | Calfina amel | Calfina maruho | Calmadol amel | Calmadol takata | Calsup | D alfa mitsubishi | D alfa sawai | Deslee | Ersibon | Kobalfa | Lonpryl maruko | Lonpryl mikasa | Onealfa fujisawa | Onealfa teijin | Platibit | Porosave | Remodellin | Toyofarol | Vitamilo alfa | Warkmin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Alphadol | Losefan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alfa d | Alfa-d3 | Alfabon | Alfabone | Alfacal | Alfadol | Alfarol | Alphagen | Alphasidol | Asidol | D calci | Hwanidol | Onealfa | Porosis | Propent | Richcalcium | Roical alpha</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Bonavit | One alpha</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">One alpha | Osteo Alfa</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol alvogen | Alpha d3 | Einsalpha | One alpha</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">1-alpha | Etalpha</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol alvogen | Alfacalcidol zentiva | Alpha d3 | Dediol | Etalpha | One alpha</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Un alfa</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alfa d | Alfad</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alfa d | Alfacip | Alpha D3 Biogal | Bon one | Medi-alpha | One alpha | Osteo Alfa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcid | Alfacalcidol aurobindo | Alfacalcidol focus | Alphacalcidol | Etalpha</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Etalpha</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">One alpha</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3 | Bon one</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">A bone | Adacidol | Adecal | Adela | Albone D | Alcal | Alfa d | Alfa one | Alfabone | Alfacal | Alfacal-d | Alfadin | Alfadol | Alfagen | Alfason | Alfasta | Alfaton | Alfawitt | Alflah | Alfox | Alpha Vit | Anibone | Bio d3 | Bioalfa | Biodol | Bon grow | Bon one | Boncidol | Bone Care | Bone Lift | Bonedol | Bonion | Cadla | Calfram | Caracal | Dyalfa | Everalfa | Facal D | Helpha | Kaid | Magcal d | Nexbone | One-alpha | Orthodol | Reboost | Recalbon | Searl Alpha | X Bone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alfadiol | Alfakalcydol | Alpha d3 | One alpha</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Etalpha</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol bergamo | Alfacalcidol cipla | Alfacalcidol prosalud | Innosfen</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">One-Alpha | Osteo-Alfa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol heaton | Alfacalcidol sandoz | Alpha d3 | Medirazin | One alpha</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3 | Alphadol | Etalfa | Etalpha | Onealfa | Oxidevit</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">One alpha</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alfacalcidol Alternova | Alfacalcidol Aristo | Alfacalcidol orifarm | Etalpha</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3 | Asravtal | Bon one | One alpha</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alfakalcidol sandoz | Alfamed | Alpha d3</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3 | Bon one | Kalsidol | Medi-alpha | One-alpha</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Un alfa</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3 | One alpha | Osivit D3</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alfadiol | Alfarol | Alfasuly | Asravtal | Calfalead | D Alfa | Etalpha | Lonpryl | Onealfa | Ostalfa | Platibit | Remodellin | Tevalfa</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alfaforcal | Alphaphorcal | Forcal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alfa calcimax | Alpha d3</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alpha d3</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">One alpha | Zodoray</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26938200">
<a name="26938200"></a>Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future. <i>J Clin Endocrinol Metab</i>. 2016;101(6):2313-2324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/26938200/pubmed" id="26938200" target="_blank">26938200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26160136">
<a name="26160136"></a>Bollerslev J, Rejnmark L, Marcocci C, et al; European Society of Endocrinology (ESE). European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. <i>Eur J Endocrinol</i>. 2015;173(2):G1-G20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/26160136/pubmed" id="26160136" target="_blank">26160136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943719">
<a name="26943719"></a>Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. <i>J Clin Endocrinol Metab</i>. 2016;101(6):2273-2283. doi:10.1210/jc.2015-3907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/26943719/pubmed" id="26943719" target="_blank">26943719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25990370">
<a name="25990370"></a>Gafni RI, Guthrie LC, Kelly MH, et al. Transient increased calcium and calcitriol requirements after discontinuation of human synthetic parathyroid hormone 1-34 (hPTH 1-34) replacement therapy in hypoparathyroidism. <i>J Bone Miner Res</i>. 2015;30(11):2112-2118. doi:10.1002/jbmr.2555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/25990370/pubmed" id="25990370" target="_blank">25990370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7677827">
<a name="7677827"></a>Hamdy N, Kanis JA, Beneton MN, et al, “Effect of Alfacalcidol on Natural Course of Renal Bone Disease in Mild to Moderate Renal Failure,” <i>BMJ</i>, 1995, 310(6976):358-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/7677827/pubmed" id="7677827" target="_blank">7677827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2013">
<a name="KDIGO.2013"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, "KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease," <i>Kidney Inter, Suppl</i>, 2013, 3:1-150.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30675420">
<a name="30675420"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). <i>Kidney Int</i>. 2017;7(suppl 1):1-59. doi: 10.1016/j.kisu.2017.04.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/30675420/pubmed" id="30675420" target="_blank">30675420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19015566">
<a name="19015566"></a>Levin A, Hemmelgarn B, Culleton B, et al, “Canadian Guidelines for the Management of Chronic Kidney Disease,” <i>CMAJ</i>, 2008, 179(11):1154-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/19015566/pubmed" id="19015566" target="_blank">19015566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18633342">
<a name="18633342"></a>Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. <i>Kidney Int</i>. 2008;74(8):1070-1078. doi:10.1038/ki.2008.343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/18633342/pubmed" id="18633342" target="_blank">18633342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22607568">
<a name="22607568"></a>Ogawa M, Ogawa T, Inoue T, Otsuka K, Nitta K. Effect of alfacalcidol therapy on the survival of chronic hemodialysis patients. <i>Ther Apher Dial</i>. 2012;16(3):248-253. doi:10.1111/j.1744-9987.2012.01061.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/22607568/pubmed" id="22607568" target="_blank">22607568</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  One-Alpha (alfacalcidol) [product monograph]. Mississauga, Ontario, Canada: Xediton Pharmaceuticals Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20090369">
<a name="20090369"></a>Reichel H. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease. <i>Nephron Clin Pract</i>. 2010;114(4):c268-c276. doi:10.1159/000276579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/20090369/pubmed" id="20090369" target="_blank">20090369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22285224">
<a name="22285224"></a>Shoben AB, Levin G, de Boer IH, et al. Variation in oral calcitriol response in patients with stages 3-4 CKD. <i>Am J Kidney Dis</i>. 2012;59(5):645-652. doi:10.1053/j.ajkd.2011.11.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/22285224/pubmed" id="22285224" target="_blank">22285224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14671054">
<a name="14671054"></a>Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. <i>Nephrol Dial Transplant</i>. 2004;19(1):179-184. doi:10.1093/ndt/gfg513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/14671054/pubmed" id="14671054" target="_blank">14671054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21851468">
<a name="21851468"></a>Tamiya H, Okamura T, Iwashiro N, Ishiki K, Yamasue H, Kasai K. Case of alfacalcidol-induced hypercalcemia presenting as bipolar disorder. <i>Psychiatry Clin Neurosci</i>. 2011;65(5):536-537. doi:10.1111/j.1440-1819.2011.02242.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/21851468/pubmed" id="21851468" target="_blank">21851468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16792136">
<a name="16792136"></a>Tarrass F, Yazidi A, Sif H, Zamd M, Benghanem MG, Ramdani B. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease. <i>Clin Nephrol</i>. 2006;65(6):415-8. doi:10.5414/cnp65415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alfacalcidol-united-states-not-available-drug-information/abstract-text/16792136/pubmed" id="16792136" target="_blank">16792136</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16467 Version 124.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
